You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Biomimetic Control of Flying Robots

    SBC: PHYSICAL SCIENCES INC.            Topic: A08056

    Physical Sciences Inc. (PSI) demonstrated in Phase I that it is possible to design a Micro Air Vehicle (MAV) which is robust to collisions by using techniques similar to what insects use to recover from collisions while still in flight. Observational studies of insects colliding with objects (high speed films of instrumented insects) conducted at the Harvard Microrobotics Laboratory show that the ...

    SBIR Phase II 2010 Department of DefenseArmy
  2. Novel Antithrombotic Diadenosine Tetraphosphate Analogs

    SBC: GLSynthesis Inc.            Topic: NCATS

    DESCRIPTION: Undesired platelet activation can be result of many common pathologies or interventions. Arterial thrombosis and the acute ischemic events that follow, such as myocardial infarction and stroke, are among the leading causes of death, incapacitation, and rising health care costs in the developed world. Therefore antiplatelet drugs have significant market share and clinical importance, ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Antithrombotic Diadenosine Tetraphosphate Analogs

    SBC: GLSynthesis Inc.            Topic: 100

    DESCRIPTION Undesired platelet activation can be result of many common pathologies or interventions Arterial thrombosis and the acute ischemic events that follow such as myocardial infarction and stroke are among the leading causes of death incapacitation and rising health care costs in the developed world Therefore antiplatelet drugs have significant market share and clinical importance ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Preclinical development of a novel antibacterial for Clostridium difficile diseas

    SBC: GLSynthesis Inc.            Topic: NIAID

    ABSTRACT Among inhibitors of Gram+ DNA polymerases IIIC and IIIE, several compounds are active against multiple strains of the anaerobic Gram+ bacterium Clostridium difficile (Cdiff). The compounds appear to be selective for Cdiff compared with other Gram+ anaerobes and aerobes, and a lead compound - 2-(3,4-dichlorobenzyl)- 7-(5-morpholinylpentyl)guanine or 359E - is active orally in protecting h ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Narrow-spectrum Agents Acting against Helicobacter pylori

    SBC: ARIETIS CORPORATION            Topic: NIAID

    DESCRIPTION provided by applicant The goal of this project is to develop a therapeutic acting specifically against Helicobacter pylori the causative agent of peptic ulcer and gastric carcinoma Roughly every other person carries the pathogen and there are an estimated cases annually of active infection in the US The currently used triple therapy is a combination of a proton pump inhibitor and broad ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Expression-Based Multi-Gene Signatures for CRC Recurrence and Chemoselection

    SBC: AMBERGEN, INC            Topic: NCI

    DESCRIPTION (provided by applicant): Colorectal cancer (CRC) is the second leading cause of cancer deaths in the U.S and Western world. Despite increased screening and advances in treatment, the mortality rate (~50,000/year) and high national health-care burden for CRC is likely to remain high unless more effective methods are developed to predict recurrence and response to chemo-radiation ther ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Isolating novel fungi for antibiotic discovery

    SBC: NOVOBIOTIC PHARMACEUTICALS, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to discover and develop novel broad-spectrum antibiotics acting against critically important human pathogens. The unmet need is especially acute for Gram-negative pathogens, where we are rapidly running out of options for treating multidrug resistant species of Pseudomonas, Acinetobacter, Burkholderia, Klebsiella and Enterobacter. T ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Portable Multimodal Biometric Devices

    SBC: Aware, Inc.            Topic: N08210

    The Portable Multimodal Biometric Device (PMBD) application developed by Aware Inc. will provide an integrated capability to employ individual-oriented identity information during the conduct of maritime and expeditionary operations. The PMBD application will rapidly establish identity information of unknown individuals encountered during the conduct of operations and improve force capacity to upd ...

    SBIR Phase II 2010 Department of DefenseNavy
  9. Therapy Against Recalcitrant C. albicans Infection

    SBC: ARIETIS CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): One of the important unresolved problems in fungal antimicrobial chemotherapy is the ineffectiveness of existing therapeutics against cells that do no exist in a rapidly-growing, planktonic population. Upon attachment to abiotic surface or tissue, C. albicans produces quiescent, drug-tolerant persister cells. Subsequent development of a biofilm protects the pat ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Drug Discovery from Slow Growing and Rare Microbial Species

    SBC: NOVOBIOTIC PHARMACEUTICALS, LLC            Topic: NIAID

    DESCRIPTION provided by applicant The overall goal of this project is to discover novel antibiotics to combat important drug resistant pathogens We are running out of treatment options for pathogens such as S aureus MRSA vancomycin resistant Enterococci VRE multidrug resistant P aeruginosa A baumannii ESBL and New Delhi metallo b lactamase producing Enterobacteriaceae and M tuberculosis Only novel ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government